LU70941A1 - - Google Patents

Info

Publication number
LU70941A1
LU70941A1 LU70941A LU70941A LU70941A1 LU 70941 A1 LU70941 A1 LU 70941A1 LU 70941 A LU70941 A LU 70941A LU 70941 A LU70941 A LU 70941A LU 70941 A1 LU70941 A1 LU 70941A1
Authority
LU
Luxembourg
Application number
LU70941A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of LU70941A1 publication Critical patent/LU70941A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/24—Y being a hetero atom
    • C07C279/26—X and Y being nitrogen atoms, i.e. biguanides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
LU70941A 1973-09-19 1974-09-17 LU70941A1 (enExample)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR7333647A FR2243684B1 (enExample) 1973-09-19 1973-09-19

Publications (1)

Publication Number Publication Date
LU70941A1 true LU70941A1 (enExample) 1975-03-06

Family

ID=9125267

Family Applications (1)

Application Number Title Priority Date Filing Date
LU70941A LU70941A1 (enExample) 1973-09-19 1974-09-17

Country Status (9)

Country Link
US (1) US3957853A (enExample)
JP (1) JPS5053520A (enExample)
BE (1) BE820072A (enExample)
DE (1) DE2444532A1 (enExample)
ES (1) ES430174A1 (enExample)
FR (1) FR2243684B1 (enExample)
GB (1) GB1432325A (enExample)
LU (1) LU70941A1 (enExample)
NL (1) NL7412427A (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2611501B1 (fr) * 1987-03-04 1991-12-06 Corbiere Jerome Nouvelles compositions pharmaceutiques pour la voie buccale a base d'acetylsalielylate de lysine et leur procede d'obtention
US6099859A (en) * 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
JP3382159B2 (ja) * 1998-08-05 2003-03-04 株式会社東芝 情報記録媒体とその再生方法及び記録方法
US6099862A (en) * 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
FR2796551B1 (fr) * 1999-07-23 2003-07-25 Lipha Nouveaux sels de metformine, leur procede d'obtention et les compositions pharmaceutiques en renfermant
FR2796940B1 (fr) * 1999-07-26 2005-04-08 Lipha Nouveaux sels de metformine, leur procede d'obtention et les compositions pharmaceutiques en renfermant
US6866866B1 (en) * 2000-11-03 2005-03-15 Andrx Labs, Llc Controlled release metformin compositions
US6790459B1 (en) 2000-11-03 2004-09-14 Andrx Labs, Llc Methods for treating diabetes via administration of controlled release metformin
US20060034922A1 (en) * 2000-11-03 2006-02-16 Andrx Labs, Llc Controlled release metformin compositions
NZ525559A (en) 2000-11-03 2005-07-29 Andrx Labs Llc Controlled release metformin compositions for the reduction of serum glucose levels in human patients with NIDDM
AU2003241537A1 (en) * 2002-05-23 2003-12-12 Andrx Corporation Biguanide formulations
JP4694841B2 (ja) 2002-09-20 2011-06-08 アンドルックス ラボズ リミテッド ライアビリティ カンパニー ビグアニドおよびチアゾリジンジオン誘導体を含有する多段階製剤
US20050051922A1 (en) * 2002-09-20 2005-03-10 Avinash Nangia Pharmaceutical composition with sodium lauryl sulfate as an extra-granular absorption/compression enhancer and the process to make the same
US20050048119A1 (en) * 2002-09-20 2005-03-03 Avinash Nangia Controlled release composition with semi-permeable membrane and poloxamer flux enhancer
US20060094782A9 (en) * 2003-10-31 2006-05-04 Wong Patrick S Compositions and dosage forms for enhanced absorption
JP4592818B2 (ja) 2007-01-29 2010-12-08 ハナル バイオファーマ カンパニー リミテッド Ｎ，ｎ−ジメチルイミドジカルボンイミド酸ジアミドの酢酸塩、その製造方法、及びそれを含む薬剤学的組成物
KR101226669B1 (ko) * 2007-09-21 2013-01-25 한올바이오파마주식회사 Ｎ,ｎ－디메틸 이미도디카르본이미딕 디아미드의 디카르복실산염, 그의 제조 방법 및 그의 약제학적 조성물
AU2008357111B2 (en) 2008-06-26 2013-05-09 Laboratorios Silanes, S.A. De C.V. A new metformin Glycinate salt for blood glucose control
WO2010146604A2 (en) 2009-06-18 2010-12-23 Exemed Pharmaceuticals Processes for preparing metformin hydrochloride
WO2011049400A2 (ko) * 2009-10-23 2011-04-28 한올바이오파마주식회사 N,n-디메틸 이미도디카르본이미딕 디아미드의 산 부가염을 포함하는 항암용 약제학적 조성물
CN101691344B (zh) * 2009-10-26 2012-10-17 漆又毛 一种二甲双胍酸式复盐化合物及制备方法
HRP20180113T1 (hr) 2010-05-26 2018-02-23 Vtv Therapeutics Llc Uporaba metformina u kombinaciji s aktivatorom glukokinaze i kompozicije koje sadrže metformin i aktivator glukokinaze
US8440723B2 (en) * 2011-05-11 2013-05-14 Banavara L. Mylari Metformin salts of salicylic acid and its congeners
SG11201406987UA (en) 2012-05-17 2014-12-30 Transtech Pharma Llc Glucokinase activator compositions for the treatment of diabetes
WO2018060962A2 (en) 2016-09-30 2018-04-05 Laboratorios Silanes S.A. De C.V. Metformin amino acid compounds and methods of using the same
WO2018060959A1 (en) 2016-09-30 2018-04-05 Laboratorios Silanes S.A. De C.V. Metformin glycinate, pharmaceutical compositions comprising the same, and methods of using the same
CN107118130A (zh) * 2017-05-11 2017-09-01 杜剑平 一类治疗肿瘤的药物化合物及其应用
EP4487909A3 (en) 2018-06-12 2025-03-19 vTv Therapeutics LLC Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs
US12391658B2 (en) 2020-02-18 2025-08-19 Vtv Therapeutics Llc Sulfoxide and sulfone glucokinase activators and methods of use thereof
CN115073330A (zh) * 2021-03-15 2022-09-20 中国医学科学院药物研究所 二甲双胍肉桂酸盐及制备方法和其组合物与用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE568513A (enExample) *
FR1295304A (fr) * 1956-05-07 1962-06-08 Equilibre Biolog L Nouveau sel de l'acide acétyl-salicylique et son procédé de préparation
US2983750A (en) * 1959-07-03 1961-05-09 Bristol Myers Co Tris methylammonium salicylate salts
GB883331A (en) * 1959-08-28 1961-11-29 Mead Johnson & Co Stable water-soluble acetylsalicylic acid derivative

Also Published As

Publication number Publication date
JPS5053520A (enExample) 1975-05-12
FR2243684B1 (enExample) 1977-01-28
FR2243684A1 (enExample) 1975-04-11
BE820072A (fr) 1975-01-16
DE2444532A1 (de) 1975-03-27
NL7412427A (nl) 1975-03-21
US3957853A (en) 1976-05-18
GB1432325A (en) 1976-04-14
ES430174A1 (es) 1976-10-16

Similar Documents

Publication Publication Date Title
AU476761B2 (enExample)
AU474593B2 (enExample)
AU474511B2 (enExample)
FR2243684B1 (enExample)
AU474838B2 (enExample)
AU476714B2 (enExample)
AU476696B2 (enExample)
AU472848B2 (enExample)
FR2220256B1 (enExample)
AU477823B2 (enExample)
AU477824B2 (enExample)
AU476873B1 (enExample)
AR193950A1 (enExample)
BG19027A1 (enExample)
AU479404A (enExample)
CH563016A5 (enExample)
CH561321A5 (enExample)
CH559090A5 (enExample)
CH217674A4 (enExample)
BG20243A1 (enExample)
BG20214A1 (enExample)
BG19655A1 (enExample)
CH563596A5 (enExample)
BG18730A1 (enExample)
BG18444A1 (enExample)